✦ LIBER ✦

Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data

✍ Scribed by David F. McDermott; Daniel J. George

Book ID: 116395457
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 450 KB
Volume: 36
Category: Article
ISSN: 0305-7372
DOI: 10.1016/j.ctrv.2009.12.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic importance of suprahepatic an

Prognostic importance of suprahepatic and intraatrial tumourthrombi in renal cell carcinoma — a retrospective analysis including immunotherapy as therapeutic option in advanced disease

✍ Klaas Winter; Jan Roigas; Andreas Wille; Serdar Deger; Dietmar Schnorr 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 202 KB

Clinical and immunomodulatory effects of

Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial

✍ Jorge A. Garcia; Tarek Mekhail; Paul Elson; Pierre Triozzi; Cheryl Nemec; Robert 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB

796 ORAL Bevacizumab, erlotinib, and ima

796 ORAL Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): Update of a Minnie Pearl Cancer Research Network phase I/II trial

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Upfront, randomized, phase 2 trial of so

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma : Clinical and biomarker analysis

✍ Eric Jonasch; Paul Corn; Lance C. Pagliaro; Carla L. Warneke; Marcella M. Johnso 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract ## BACKGROUND: The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low‐dose interferon‐alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC). ## METHODS: Untreated patients with cle

PCN70 COST EFFECTIVENESS ANALYSIS OF SUN

PCN70 COST EFFECTIVENESS ANALYSIS OF SUNITINIB, BEVACIZUMAB + INTERFERON-ALFA AND TEMSIROLIMUS AS FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN

✍ E Remák; H Vioix; R Sandin; U Harmenberg; A Ullén; P Sandström 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

An EORTC phase II study of the efficacy

An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma

✍ A. Pawinski; A.T. van Oosterom; R. de Wit; S. Fosså; J. Croles; A. Svedberg; M.A 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 386 KB